Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cabozantinib · Cabometyx, Cometriq

Small molecule · Inhibitor of MET proto-oncogene receptor tyrosine kinase (MET), vascular endothelial growth factor receptor 1 (FLT1) and vascular endothelial growth factor receptor 2 (KDR) · developed by Exelixis

Approved FDA, Nov 2012
EXEL Developer
3 Registered trials

What is Cabozantinib?

Cabozantinib is an approved small-molecule drug studied in Medullary Thyroid Cancer, RCC, Renal Cell Carcinoma.

At a glance

Also known as
Cabometyx, Cometriq, Resniben, XL184
Drug type
Small molecule
Targets
MET proto-oncogene receptor tyrosine kinase (MET), vascular endothelial growth factor receptor 1 (FLT1), vascular endothelial growth factor receptor 2 (KDR), vascular endothelial growth factor receptor 3 (FLT4), AXL receptor tyrosine kinase (AXL), RET proto-oncogene (RET)
Mechanism
Inhibitor of MET proto-oncogene receptor tyrosine kinase (MET), vascular endothelial growth factor receptor 1 (FLT1) and vascular endothelial growth factor receptor 2 (KDR)
Pathways
tumor angiogenesis, oncogenesis, metastasis, tumor microenvironment maintenance, drug resistance
Therapy area
Oncology
Developer
Exelixis (EXEL)
Also in trials of
LLY
FDA status
Approved as Cabometyx, Cometriq, Resniben (November 29, 2012), NDA203756 · FDA label
UNII
1C39JW444G

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 19, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01896479 Phase 4 Medullary Thyroid Cancer Active not recruiting EXEL
NCT03937219 Phase 3 Renal Cell Carcinoma Active not recruiting EXEL
NCT05931393 Phase 2 RCC Recruiting EXEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Medullary Thyroid CancerRCCRenal Cell Carcinoma

Other drugs acting on MET / FLT1 / KDR / FLT4 / AXL / RET

More from Exelixis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.

Follow EXEL, the company behind Cabozantinib

See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EXEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.